AVTX
Avalo Therapeutics·NASDAQ
--
--(--)
--
--(--)
AVTX fundamentals
Avalo Therapeutics (AVTX) released its earnings on Aug 7, 2025: revenue was 0 (YoY --), met estimates; EPS was -1.92 (YoY +86.35%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-1.92
+86.35%
Report date
Aug 7, 2025
EPS
Actual | -1036.8 | -518.4 | -460.8 | -460.8 | -921.6 | -518.4 | -489.6 | -460.8 | -576 | -331.2 | 81.6 | -237.6 | -204 | -141.6 | -26.4 | -10.1 | -141 | -14.07 | -2.83 | -2.3 | -1.25 | -1.92 | ||||||||
Forecast | -297.6 | -302.4 | -273.6 | -432 | -480 | -480 | -483.84 | -426.24 | -360 | -424.8 | -210.6 | -176 | -232.8 | -192 | -264 | -4.8 | -1.18 | -6.7 | -1.19 | -0.1683 | -1.332 | -1.4022 | ||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -248.39% | -71.43% | -68.42% | -6.67% | -92.00% | -8.00% | -1.19% | -8.11% | -60.00% | +22.03% | +138.75% | -35.00% | +12.37% | +26.25% | +90.00% | -110.42% | -11849.15% | -110.00% | -137.82% | -1266.61% | +6.16% | -36.93% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | 2.75M | 1.34M | 1.11M | 1.50M | 473.00K | 3.35M | 1.35M | 198.00K | 1.17M | 1.03M | 14.95M | 901.00K | 475.00K | 643.00K | 236.00K | 574.00K | 0 | 0 | 249.00K | 200.00K | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | 1.84M | 2.25M | 1.50M | 0 | 539.33K | 333.33K | 1.12M | 1.02M | 645.50K | 1.19M | 1.26M | 3.61M | 1.00M | 1.00M | 1.00M | 300.00K | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +49.46% | -40.53% | -25.93% | 0.00% | -12.30% | +906.50% | +21.01% | -80.55% | +81.72% | -12.94% | +1088.08% | -75.05% | -52.50% | -35.70% | -76.40% | +91.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What guidance did Avalo Therapeutics's management provide for the next earnings period?What is Avalo Therapeutics's latest dividend and current dividend yield?What does Avalo Therapeutics do and what are its main business segments?What is the market's earnings forecast for Avalo Therapeutics next quarter?Did Avalo Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from Avalo Therapeutics’s earnings call?What is the revenue and EPS growth rate for Avalo Therapeutics year over year?What factors drove the changes in Avalo Therapeutics's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
